<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649426</url>
  </required_header>
  <id_info>
    <org_study_id>CLN 0777</org_study_id>
    <nct_id>NCT02649426</nct_id>
  </id_info>
  <brief_title>A Study of the ReCor Medical Paradise System in Clinical Hypertension</brief_title>
  <acronym>RADIANCE-HTN</acronym>
  <official_title>The &quot;RADIANCE-HTN&quot; Study. A Study of the ReCor Medical Paradise System in Clinical Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReCor Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReCor Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO)
      designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation
      System in two distinct populations of hypertensive subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with essential hypertension controlled on 1 or 2 antihypertensive medications or
      uncontrolled on 0-2 antihypertensive medications will be included in the RADIANCE Solo cohort
      while subjects with treatment resistant hypertension on a minimum of 3 antihypertensive
      medications will be included in the RADIANCE Trio cohort. Prior to randomization, subjects
      will be hypertensive in the absence of hypertension medication (SOLO) or despite the presence
      of a stabilized, single pill, triple, fixed dose antihypertensive medication regimen (TRIO).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean reduction in average daytime ambulatory systolic BP</measure>
    <time_frame>from baseline to 2 months post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in average 24-hr/night-time ambulatory systolic BP</measure>
    <time_frame>from baseline to 2 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in average daytime/24-hr/night-time diastolic BP</measure>
    <time_frame>from baseline to 2 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertensive or hypotensive emergency resulting in hospitalization</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke, transient ischemic attack, cerebrovascular accident</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End stage renal disease</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal artery or vascular complications requiring intervention</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant embolic events resulting in end organ damage</measure>
    <time_frame>from baseline to 1 month and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related pain lasting &gt; 2 days</measure>
    <time_frame>from baseline to 1 month and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal injury</measure>
    <time_frame>from baseline to 1 month and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant (&gt;50%) and severe (&gt;75%) new onset renal stenosis</measure>
    <time_frame>from baseline to 6, 12, 24 and 36 months post-procedure</time_frame>
    <description>as diagnosed by duplex ultrasound and confirmed by renal CTA/MRA or as diagnosed/confirmed by study defined renal CTA/MRA at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major access site complications</measure>
    <time_frame>from baseline to 1 month and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Hypertension</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Ultrasound Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Paradise® Renal Denervation Ultrasound System</intervention_name>
    <description>Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.</description>
    <arm_group_label>Ultrasound Renal Denervation</arm_group_label>
    <other_name>renal denervation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.</description>
    <arm_group_label>Sham Procedure</arm_group_label>
    <other_name>renal angiogram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        TRIO and SOLO Inclusion Criteria:

          -  Appropriately signed and dated informed consent

          -  Age ≥18 and ≤75 years at time of consent

          -  Documented history of essential hypertension

          -  SOLO Cohort only: Either an average seated office BP &lt; 180/110 mmHg at screening visit
             while on a stable regimen of 1 or 2 antihypertensive medications for at least 4 weeks
             prior to consent or an average seated office BP ≥ 140/90 mmHg &lt;180/110 mmHg despite
             lifestyle measures on no antihypertensive medications

          -  TRIO Cohort only: Average seated office BP ≥ 140/90 mmHg at screening visit while on a
             stable regimen of at least 3 antihypertensive medications of different classes
             including a diuretic for at least 4 weeks prior to consent

          -  Documented daytime ABP ≥ 135/85 mmHg and &lt; 170/105 mmHg after 4-week washout/run-in
             period (SOLO cohort) or after 4-week stabilization period (TRIO cohort)

          -  Suitable renal anatomy compatible with the renal denervation procedure and documented
             by renal CTA or MRA of good quality performed within one year prior to consent (a CTA
             or MRA will be obtained in patients without a recent (≤1 year) renal imaging)

          -  Able and willing to comply with all study procedures

        Solo Exclusion Criteria:

          -  Renal artery anatomy on either side, ineligible for treatment including:

               -  Main renal artery diameter &lt; 4 mm and &gt; 8 mm

               -  Main renal artery length &lt; 25 mm

               -  A single functioning kidney

               -  Presence of abnormal kidney (or secreting adrenal) tumors

               -  Renal artery with aneurysm

               -  Pre-existing renal stent or history of renal artery angioplasty

               -  Prior renal denervation procedure

               -  Fibromuscular disease of the renal arteries

               -  Presence of renal artery stenosis of any origin ≥ 30%

               -  Accessory arteries with diameter ≥ 2mm &lt;4 mm and &gt; 8 mm*

          -  Evidence of active infection within 7 days of procedure

          -  Iliac/femoral artery stenosis precluding insertion of the Paradise Catheter

          -  Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma Hb1Ac ≥
             9.0%)

          -  Documented history of chronic active inflammatory bowel disorders such as Chrohn's
             disease or ulcerative colitis

          -  eGFR of &lt;40 mL/min/1.73 m2 (by Modification of Diet in Renal Disease formula)

          -  Brachial circumference ≥ 42 cm

          -  Any history of cerebrovascular event (e.g. stroke, transient ischemic event,
             cerebrovascular accident)

          -  Any history of severe cardiovascular event (myocardial infarction, CABG, acute heart
             failure requiring hospitalization (NYHA III-IV)

          -  Documented confirmed episode(s) of stable or unstable angina

          -  Documented repeat (&gt;1) hospitalization for hypertensive crisis within the prior 12
             months

          -  Prescribed to any standard antihypertensive of cardiovascular medication (e.g. beta
             blockers) for other chronic conditions (e.g. ischemic heart disease) such that
             discontinuation might pose serious risk to health

          -  Documented history of persistent or permanent atrial tachyarrhythmia

          -  Active implantable medical device (e.g. ICD or CRT-D; neuromodulator/spinal
             stimulator; baroreflex stimulator)

          -  Chronic oxygen support or mechanical ventilation other than nocturnal respiratory
             support for sleep apnea.

          -  Primary pulmonary hypertension

          -  Documented contraindication or allergy to contrast medium not amenable to treatment

          -  Limited life expectancy of &lt; 1 year at the discretion of the Investigator

          -  Any known, unresolved history of drug use or alcohol dependency, lacks the ability to
             comprehend or follow instructions, or for any reason in the opinion of the
             investigator, would be unlikely or unable to comply with study protocol requirements
             or whose participation may result in data analysis confounders (e.g. night shift
             workers)

          -  Pregnant, nursing or planning to become pregnant (negative pregnancy test required,
             documented within a maximum of 7 days prior to procedure for all women of child
             bearing potential. Documentation of effective contraception is also required for women
             of child bearing potential) Concurrent enrollment in any other investigational drug or
             device trial (participation in non-interventional Registries is acceptable)

        TRIO Exclusion Criteria

          -  Renal artery anatomy on either side, ineligible for treatment including:

               -  Main renal artery diameter &lt; 4 mm and &gt; 8 mm

               -  Main renal artery length &lt; 25 mm

               -  A single functioning kidney

               -  Presence of abnormal kidney (or secreting adrenal) tumors

               -  Renal artery with aneurysm

               -  Pre-existing renal stent or history of renal artery angioplasty

               -  Prior renal denervation procedure

               -  Fibromuscular disease of the renal arteries

               -  Presence of renal artery stenosis of any origin ≥ 30%

               -  Accessory arteries with diameter ≥2 mm &lt;4 mm and &gt; 8 mm*

          -  Iliac/femoral artery stenosis precluding insertion of the Paradise Catheter

          -  Evidence of active infection within 7 days of procedure

          -  Secondary hypertension not including sleep apnea (documented through clinical work up
             within the 12 months prior to consent- see protocol body for details)

          -  Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma Hb1Ac ≥
             9.0%)

          -  Documented history of chronic active inflammatory bowel disorders such as Chrohn's
             disease or ulcerative colitis

          -  eGFR of &lt;40 mL/min/1.73 m2 (by Modification of Diet in Renal Disease formula)

          -  Brachial circumference ≥ 42 cm

          -  Any history of cerebrovascular event (e.g. stroke, transient ischemic event,
             cerebrovascular accident) within 3 months prior to consent

          -  Any history of severe cardiovascular event (myocardial infarction, CABG, acute heart
             failure requiring hospitalization (NYHA III-IV) within 3 months prior to consent

          -  Documented confirmed episode(s) of unstable angina within 3 months prior to consent

          -  Documented intolerance or contraindication for any of the antihypertensive drugs
             prescribed as a requirement of the study protocol

          -  Prescribed to any standard anti-hypertensive CV medication (other than beta blockers)
             for other chronic conditions (e.g. ischemic heart disease) such that discontinuation
             might pose serious risk to health

          -  Documented history of persistent or permanent atrial tachyarrhythmia

          -  Active implantable medical device (e.g. ICD or CRT-D; neuromodulator/spinal
             stimulator; baroreflex stimulator)

          -  Chronic oxygen support or mechanical ventilation other than nocturnal respiratory
             support for sleep apnea.

          -  Primary pulmonary hypertension

          -  Documented contraindication or allergy to contrast medium not amenable to treatment

          -  Limited life expectancy of &lt; 1 year at the discretion of the Investigator

          -  Any known, unresolved history of drug use or alcohol dependency, lacks the ability to
             comprehend or follow instructions, or for any reason in the opinion of the
             investigator, would be unlikely or unable to comply with study protocol requirements
             or whose participation may result in data analysis confounders (e.g. night shift
             workers)

          -  Pregnant, nursing or planning to become pregnant (documented negative pregnancy test
             required documented within a maximum of 7 days prior to procedure for all women of
             child bearing potential. Documentation of effective contraception is also required for
             women of child bearing potential)

          -  Concurrent enrollment in any other investigational drug or device trial (participation
             in non-interventional Registries is acceptable)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Mauri, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Azizi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges-Pompidou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Reeve-Stoffer, PhD</last_name>
    <phone>+44 7947 748006</phone>
    <email>hreeve-stoffer@recormedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meital Horesh-Bar, BA</last_name>
    <phone>+1 650 542-9785</phone>
    <email>mhoresh-bar@recormedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Blue, RN</last_name>
      <phone>205-975-4338</phone>
      <email>mblue@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Calhoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom McElderry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Maddox, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Santeliz</last_name>
      <phone>323-783-5220</phone>
      <email>David.N.Santeliz@kp.org</email>
    </contact>
    <investigator>
      <last_name>Somjot Brar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Rashid</last_name>
      <phone>424-315-2501</phone>
      <email>Mohamad.Rashid@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Kirin Bhatia, BA</last_name>
      <phone>(310) 248-8245</phone>
      <email>Kirin.bhatia@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Florian Radar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Health Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Seiler, RN</last_name>
      <phone>916-887-4173</phone>
      <email>seilerb@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Pei-Hsiu Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Roberts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Ericson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Stamford Hospital</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Garcia</last_name>
      <phone>203-276-7880</phone>
      <email>jgarcia1@stamhealth.org</email>
    </contact>
    <investigator>
      <last_name>David Hsi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cardiac and Vascular Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Boyette</last_name>
      <phone>352-244-0208</phone>
      <email>aboyette@tcavi.com</email>
    </contact>
    <investigator>
      <last_name>Matheen Khuddus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fiebach</last_name>
      <phone>404-686-7468</phone>
      <email>amanda.fiebach@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Chandan Devireddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Health Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Brown</last_name>
      <email>timothy.brown@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Atul Chugh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Heart and Vascular Insitute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristine Hardy</last_name>
      <phone>504-842-6832</phone>
      <email>chardy@ochsner.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Jarvis</last_name>
      <phone>504-842-8093</phone>
      <email>maria.jarvis@ochsner.org</email>
    </contact_backup>
    <investigator>
      <last_name>John P Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Re, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tyrone Collins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajan Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Do</last_name>
      <phone>617-643-1372</phone>
      <email>ddo2@partners.org</email>
    </contact>
    <investigator>
      <last_name>Doug Drachman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randall Zusman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Garasic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Won</last_name>
      <phone>617-732-7381</phone>
      <email>awon1@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Naomi Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Peterson, RN, BA, LNC, CCRP</last_name>
      <phone>612-863-6051</phone>
      <email>rose.peterson@allina.com</email>
    </contact>
    <investigator>
      <last_name>Yale L Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Schwartz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renown Institute for Heart&amp; Vascular Health</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla Nelson</last_name>
      <phone>775-982-2217</phone>
      <email>pnelson@renown.org</email>
    </contact>
    <contact_backup>
      <last_name>Bridget Neumann</last_name>
      <email>BNeumann@renown.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Bloch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luot Lewis, RN</last_name>
      <phone>609-893-1200</phone>
      <phone_ext>5022</phone_ext>
      <email>LewisL@Deborah.org</email>
    </contact>
    <investigator>
      <last_name>Kintur Sanghvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Cobos</last_name>
      <phone>646-501-2897</phone>
      <email>Stanley.Cobos@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Sripal Bangalore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University / NewYork Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candido Batres, MD</last_name>
      <phone>212-342-3486</phone>
      <email>cb2269@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay Kirtane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyrone Wade</last_name>
      <phone>919-962-4896</phone>
      <email>tyrone_wade@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>George Stouffer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence Semenec, RN</last_name>
      <phone>216-983-4724</phone>
      <email>Terence.Semenec@Uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Jackson Wright, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Zidar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Brienza</last_name>
      <phone>216-444-6321</phone>
      <email>BRIENZR@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Bajzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Katof</last_name>
      <phone>215-762-3369</phone>
      <email>nsk39@drexel.edu</email>
    </contact>
    <investigator>
      <last_name>Jessie Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Paladugu</last_name>
      <phone>843-876-5009</phone>
      <email>paladugc@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Tom Todoran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Basile, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarita Madell</last_name>
      <phone>615-343-9071</phone>
      <email>Sarita.m.madell@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Pete Fong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Neagle</last_name>
      <phone>801-585-1897</phone>
      <email>sarah.neagle@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenice Herrera</last_name>
      <phone>801-581-6177</phone>
      <email>jenice.herrera@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Josephine Abraham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Persu, MD, PhD</last_name>
      <email>alexandre.persu@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Alexandre Persu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André - CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Gosse, MD</last_name>
      <email>philippe.gosse@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Gosse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Lantelme, MD, PhD</last_name>
      <email>pierre.lantelme@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Lantelme, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Azizi, MD, PhD</last_name>
      <email>michel.azizi@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Azizi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Sapoval, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes, Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athul Pathak, MD, PhD</last_name>
      <email>apathak@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Athul Pathak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars C Rump, MD, PhD</last_name>
      <email>Christian.Rump@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Lars C Rump, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Schmieder, MD, PhD</last_name>
      <email>roland.schmieder@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Roland Schmieder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinic of Saarland</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Mahfoud, MD</last_name>
      <email>Felix.Mahfoud@uniklinikum-saarland.de</email>
    </contact>
    <investigator>
      <last_name>Felix Mahfoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Lurz, MD, PhD</last_name>
      <email>philipp.lurz@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Philipp Lurz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Lübeck GmbH</name>
      <address>
        <city>Lübeck</city>
        <zip>23560</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Weil, MD, PhD</last_name>
      <email>Joachim.Weil@Sana.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Weil, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Hospital</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abraham A Kroon, MD, PhD</last_name>
      <email>aa.kroon@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Abraham A Kroon, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arno H Ruiter</last_name>
      <email>a.ruiter@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Joost Daemen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter J Blankestijn, MD</last_name>
      <email>P.J.Blankestijn@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Peter J Blankestijn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Witkowski, MD, PhD</last_name>
      <email>witkowski@hbz.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Witkowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cardiac.research@rbch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Terry Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Beckett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clare Bent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Bala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amit Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College London, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW7 2AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Team</last_name>
      <phone>0044 207 594 9833</phone>
      <email>hypertension@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Justin Davies, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darrel Francis, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neil Chapman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Essex Cardiothoracic Centre - Basildon &amp; Thurrock University Hospitals</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Team</last_name>
      <phone>0044 (0)1268 524900</phone>
      <email>BloodPressureStudy@btuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jeremy Sayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sudha Iyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Robinson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Keeble, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Conquest Hospital - Hastings</name>
      <address>
        <city>East Sussex</city>
        <zip>TN37 7RD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gerber, MD</last_name>
      <email>r.gerber@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Robert Gerber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital (Wonford)</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Sharp, MD</last_name>
      <email>andrew.sharp5@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Christine Anning</last_name>
      <email>c.anning@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Sharp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hibba Kurdi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard J. D'Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uwadiegwu W. Okoroafor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Watkinson, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Saxena, MD</last_name>
      <email>m.saxena@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Melvin Lobo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manish Saxena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David J. Collier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajay K. Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathur Anthony, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>denervation</keyword>
  <keyword>resistant hypertension</keyword>
  <keyword>essential hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>to be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

